Unspecified systolic (congestive) heart failure
Methodology & AI Transparency ⓘ
Unspecified systolic (congestive) heart failure Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Unspecified systolic (congestive) heart failure uses ICD-10 I50.20 across Heart & Vascular specialty care.
- 3 Typical cash cost range: Primary evaluation for Unspecified systolic (congestive) heart failure incorporates cardiopulmonary biomarker stratification [Unspecified systolic (congestive) heart failure I50.20] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Unspecified systolic (congestive) heart failure: maintaining Left Ventricular Ejection in Unspecified systolic (congestive) heart failure (I50.20: Fraction (LVEF)) within 55% – 70% (I50.20).
Ask our AI Specialists anything about Unspecified systolic (congestive) heart failure
What Is Unspecified systolic (congestive) heart failure?
Recognized across U.S. clinical coding as I50.20 (Heart & Vascular), Unspecified systolic (congestive) heart failure is evaluated via cardiopulmonary biomarker stratification [Unspecified systolic (congestive) heart failure I50.20] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Unspecified systolic (congestive) heart failure (code I50.20) is fibrotic extracellular matrix in Unspecified systolic (congestive) heart failure (I50.20: deposition), which Heart & Cardiovascular Disease clinicians address while surveilling Left Ventricular Ejection in Unspecified systolic (congestive) heart failure (I50.20: Fraction (LVEF)) (55% – 70% (I50.20)).
Common Symptoms & Clinical Signs
- • Presentation of Unspecified systolic (congestive) heart failure (I50.20): palpitations, skipped beats, in Unspecified systolic (congestive) heart failure (I50.20: or irregular resting)
- • Secondary Unspecified systolic (congestive) heart failure clinical sign: unexplained lower-extremity ankle in Unspecified systolic (congestive) heart failure (I50.20: edema or rapid)
- • Symptom flares in Unspecified systolic (congestive) heart failure correlating with Left Ventricular Ejection in Unspecified systolic (congestive) heart failure (I50.20: Fraction (LVEF)) deviation outside 55% – 70% (I50.20)
- • Functional heart & vascular impact requiring cardiopulmonary biomarker stratification [Unspecified systolic (congestive) heart failure I50.20] evaluation (I50.20)
Unspecified systolic (congestive) heart failure Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I50.20 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Unspecified systolic (congestive) heart failure (I50.20: Fraction (LVEF)) | 55% – 70% (I50.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: NT-proBNP [Unspecified systolic (congestive) heart failure I50.20] | < 100 pg/mL (I50.20) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Unspecified systolic (congestive) heart failure I50.20] | < 14 ng/L (I50.20) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Unspecified systolic (congestive) heart failure
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Acetazolamide Diamox • RxCUI 197303 | Carbonic Anhydrase Inhibitor | 89% | $0.0935 | $ 6.66 /mo |
| Amiloride Hydrochloride Midamor • RxCUI 977880 | Potassium-sparing Diuretic | 85% | $0.1898 | $ 9.96 /mo |
| Amiloride Hydrochloride and Hydrochlorothiazide Amiloride Hydrochloride and Hydrochlorothiazide Generic • RxCUI 977883 | Thiazide Diuretic | 91% | $0.4381 | $ 26.24 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unspecified systolic (congestive) heart failure)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Among the 300 patients who were randomized (median age, 61 years [interquartile range {IQR}, 52-68 years]; 64 [21%] women; 178 [59%] with type 2 diabetes; median LVEF of 25% [IQR, 19%-33%]; median N-terminal pro-B-type... JAMA • 2016-08-02 • Randomized Controlled Trial | N = 154 | 88/100 | PMID 27483064 ↗ |
| Can This Approach Help? Inside the Latest Research on Obstructive sleep apnea/hypopnea syndrome and poor response to sertraline in Obstructive sleep apnea/hypopnea syndrome is associated with a relatively poor response to sertraline treatment for depression. The Journal of clinical psychiatry • 2012-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 21903027 ↗ |
| Can This Approach Help? Inside the Latest Research on Losartan and captopril on QT dispersion in older adults patients with heart Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan. Lancet (London, England) • 1999-07-31 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 10437875 ↗ |
Unspecified systolic (congestive) heart failure Patient Community & “People Like Me” Threads
Filter Unspecified systolic (congestive) heart failure community threads and patient logs by age, biological sex, dosage, and treatment duration.